Analysts forecast that Illumina, Inc. (NASDAQ:ILMN) will post sales of $735.16 million for the current quarter, Zacks reports. Seven analysts have provided estimates for Illumina’s earnings, with the lowest sales estimate coming in at $728.41 million and the highest estimate coming in at $741.30 million. Illumina reported sales of $619.35 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.7%. The company is expected to issue its next quarterly earnings results on Tuesday, January 30th.

On average, analysts expect that Illumina will report full-year sales of $735.16 million for the current year, with estimates ranging from $2.70 billion to $2.72 billion. For the next fiscal year, analysts forecast that the business will post sales of $3.07 billion per share, with estimates ranging from $2.97 billion to $3.19 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Illumina.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same period last year, the company earned $0.97 earnings per share. Illumina’s quarterly revenue was up 17.6% compared to the same quarter last year.

Several brokerages have commented on ILMN. BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $252.00 price objective on the stock in a report on Tuesday, December 5th. Citigroup raised their price objective on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Barclays raised their price objective on Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Finally, Bank of America raised their price objective on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. Illumina has a consensus rating of “Buy” and an average price target of $201.98.

In other Illumina news, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $202.23, for a total transaction of $29,323.35. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the transaction, the director now directly owns 9,088 shares in the company, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. Insiders sold 136,421 shares of company stock worth $28,489,101 over the last ninety days. Corporate insiders own 0.89% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Illumina by 2.6% during the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after buying an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. raised its position in Illumina by 3.1% in the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock valued at $500,416,000 after purchasing an additional 76,452 shares during the period. Capital World Investors raised its position in Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after purchasing an additional 410,000 shares during the period. TIAA CREF Investment Management LLC raised its position in Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after purchasing an additional 527,548 shares during the period. Finally, Winslow Capital Management LLC purchased a new stake in Illumina in the second quarter valued at $211,584,000. 91.75% of the stock is currently owned by institutional investors.

Shares of Illumina (NASDAQ ILMN) opened at $214.11 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina has a 1-year low of $121.47 and a 1-year high of $230.72. The company has a market capitalization of $31,776.90, a P/E ratio of 63.64, a price-to-earnings-growth ratio of 3.59 and a beta of 0.79.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect Illumina, Inc. (ILMN) Will Announce Quarterly Sales of $735.16 Million” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/12/zacks-analysts-expect-illumina-inc-ilmn-will-announce-quarterly-sales-of-735-16-million.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.